Experimental cell therapy takes on tough leukemia
NCT ID NCT07572136
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times
Summary
This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on cancer cells. Up to 57 participants will receive chemotherapy followed by the modified cells to see if it is safe and what dose works best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TSLPR-CART cells (modified immune cells) plus chemotherapy (cyclophosphamide and fludarabine)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat B-cell acute lymphoblastic leukemia that has not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 57 participants, focused on safety and dosing. The treatment may not work, and there are risks from chemotherapy and the modified cells, including severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can donor immune cells be engineered to fight blood cancer?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests